Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
05
2019
accepted:
27
11
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
31
3
2020
Statut:
epublish
Résumé
It is now well established that for tumour growth and survival, tumour vasculature is an important element. Studies have demonstrated that ultrasound-stimulated microbubble (USMB) treatment causes extensive endothelial cell death leading to tumour vascular disruption. The subsequent rapid vascular collapse translates to overall increases in tumour response to various therapies. In this study, we explored USMB involvement in the enhancement of hyperthermia (HT) treatment effects. Human prostate tumour (PC3) xenografts were grown in mice and were treated with USMB, HT, or with a combination of the two treatments. Treatment parameters consisted of ultrasound pressures of 0 to 740 kPa, the use of perfluorocarbon-filled microbubbles administered intravenously, and an HT temperature of 43°C delivered for various times (0-50 minutes). Single and multiple repeated treatments were evaluated. Tumour response was monitored 24 hours after treatments and tumour growth was monitored for up to over 30 days for a single treatment and 4 weeks for multiple treatments. Tumours exposed to USMB combined with HT exhibited enhanced cell death (p<0.05) and decreased vasculature (p<0.05) compared to untreated tumours or those treated with either USMB alone or HT alone within 24 hours. Deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining and cluster of differentiation 31 (CD31) staining were used to assess cell death and vascular content, respectively. Further, tumours receiving a single combined USMB and HT treatment exhibited decreased tumour volumes (p<0.05) compared to those receiving either treatment alone when monitored over the duration of 30 days. Additionally, tumour response monitored weekly up to 4 weeks demonstrated a reduced vascular index and tumour volume, increased fibrosis and lesser number of proliferating cells with combined treatment of USMB and HT. Thus in this study, we characterize a novel therapeutic approach that combines USMB with HT to enhance treatment responses in a prostate cancer xenograft model in vivo.
Identifiants
pubmed: 31851698
doi: 10.1371/journal.pone.0226475
pii: PONE-D-19-14627
pmc: PMC6919613
doi:
Substances chimiques
Platelet Endothelial Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226475Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Oncol Rep. 2018 Apr;39(4):1609-1618
pubmed: 29436690
Ultrasound Med Biol. 1999 Jul;25(6):871-87
pubmed: 10461714
Oncoscience. 2016 Mar 24;3(3-4):98-108
pubmed: 27226983
Int J Hyperthermia. 2005 Dec;21(8):745-53
pubmed: 16338857
Ultrasound Med Biol. 2008 May;34(5):834-40
pubmed: 18207311
J Natl Cancer Inst. 2018 Sep 1;110(9):1009-1018
pubmed: 29506145
PLoS One. 2014 Dec 30;9(12):e111083
pubmed: 25549352
J Biol Chem. 1989 Nov 25;264(33):20017-24
pubmed: 2584205
Nature. 2003 May 8;423(6936):153-6
pubmed: 12736680
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Br J Cancer. 2002 May 20;86(10):1597-603
pubmed: 12085210
Cancer Res. 2000 Jan 15;60(2):321-7
pubmed: 10667583
J Biol Chem. 2000 Mar 24;275(12):8872-9
pubmed: 10722733
Int J Hyperthermia. 2011;27(1):42-52
pubmed: 21204622
Med Princ Pract. 2005;14 Suppl 1:35-48
pubmed: 16103712
Int J Hyperthermia. 2008 Feb;24(1):3-15
pubmed: 18214765
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26
pubmed: 17493790
Evid Based Complement Alternat Med. 2013;2013:672873
pubmed: 23662149
Ultrasound Med Biol. 2013 Aug;39(8):1376-87
pubmed: 23643061
Science. 2003 May 16;300(5622):1155-9
pubmed: 12750523
Science. 2001 Jul 13;293(5528):293-7
pubmed: 11452123
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):605-11
pubmed: 8226155
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2033-41
pubmed: 22778441
Int J Nanomedicine. 2018 Jun 19;13:3529-3539
pubmed: 29950833
Int J Hyperthermia. 2005 Dec;21(8):761-7
pubmed: 16338859
Cell Death Discov. 2016 Jun 13;2:16039
pubmed: 27551529
Nat Med. 2011 Nov 07;17(11):1359-70
pubmed: 22064426
Sci Rep. 2016 Nov 14;6:36992
pubmed: 27841344
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
Mol Med Rep. 2014 Dec;10(6):3282-8
pubmed: 25324182
Eur J Cancer. 1977 Jan;13(1):65-9
pubmed: 844475
Genes Cancer. 2011 Dec;2(12):1085-96
pubmed: 22866200
Ultrasound Med Biol. 2010 Jun;36(6):935-48
pubmed: 20447755
Dis Model Mech. 2014 Mar;7(3):363-72
pubmed: 24487407
Endocr Rev. 1992 Feb;13(1):18-32
pubmed: 1372863
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
PLoS One. 2014 Oct 02;9(10):e109102
pubmed: 25275645
Ann Surg Oncol. 2013 Apr;20(4):1105-13
pubmed: 23456378
Int J Nanomedicine. 2015 Feb 25;10:1609-23
pubmed: 25759583
Int J Mol Sci. 2015 Nov 10;16(11):26880-913
pubmed: 26569225
Natl Cancer Inst Monogr. 1982 Jun;61:325-32
pubmed: 7177183
Sci Rep. 2018 Jun 7;8(1):8720
pubmed: 29880902
PLoS One. 2014 Apr 15;9(4):e93888
pubmed: 24736631
Anticancer Res. 2019 May;39(5):2307-2315
pubmed: 31092422
Int J Cancer. 2013 Jun 15;132(12):2956-66
pubmed: 23225339
J Acoust Soc Am. 2015 Dec;138(6):EL493-7
pubmed: 26723356
Ann Oncol. 2002 Aug;13(8):1173-84
pubmed: 12181239
Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18
pubmed: 11212876
Cancer Res. 1984 Oct;44(10 Suppl):4721s-4730s
pubmed: 6467226
Br J Cancer. 2012 Jul 24;107(3):469-76
pubmed: 22790798
PLoS One. 2012;7(12):e52307
pubmed: 23284980
Radiat Res. 1988 May;114(2):297-306
pubmed: 2453896
Ultrasound Med Biol. 2012 Nov;38(11):1958-69
pubmed: 22980406
Int J Radiat Biol. 2006 Aug;82(8):549-59
pubmed: 16966182